Michael Holmes

Michael Holmes, Ph.D. joined Tessera in December 2021 as Chief Scientific Officer. He has over 20 years of experience working on the development and clinical translation of different genome editing- and gene therapy-based strategies for the treatment of inherited and acquired diseases. Michael has a proven track record of translating genomic engineering technologies to product candidates as evidenced by leading ten therapeutic programs across a landscape of ex vivo and in vivo therapies.

Prior to joining Tessera, Michael served as the Chief Scientific Officer with Ambys Medicines, where he led the research and development efforts in the identification, creation, and advancement of novel therapies for severe liver diseases. Previously, he worked for 17 years at Sangamo Therapeutics, Inc. raising through the ranks to Senior Vice President and Chief Technology Officer. During this time, he was heavily involved in the company’s research and pipeline development of genetic therapies.